| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
MAHMA NONOate targets the nitric oxide signaling pathway. As an NO donor, it releases nitric oxide, which activates soluble guanylate cyclase (sGC) and increases intracellular cGMP levels. This leads to vasodilation, inhibition of platelet aggregation, and modulation of various cellular signaling pathways. Its "target" is the NO/cGMP signaling pathway and downstream effectors.
|
|---|---|
| ln Vitro |
MAHMA NONOate (0.1 nM-100 μM) suppresses platelet aggregation that is triggered by ADP or collagen in a dose-dependent manner[1]. With log IC50 values of 7.18 and 6.16 for pulmonary artery and platelet aggregation, respectively, MAHMA NONOate exhibits inhibitory effects[1].
In vitro, MAHMA NONOate releases nitric oxide in a pH- and temperature-dependent manner, with a half-life of approximately 1-2 minutes at physiological pH (7.4) and 37°C. It is used to study the effects of NO on various cellular processes including vasodilation, neurotransmission, and immune function. Its activity is measured by the release of NO and the subsequent activation of sGC and cGMP production. |
| ln Vivo |
In vivo, MAHMA NONOate (0.3-10 nmol/kg/min; intravenous once) exhibits vasodepressant and platelet inhibitory effects[2].
In vivo, MAHMA NONOate is used as a pharmacological tool to deliver nitric oxide in animal models. It causes vasodilation, reduces blood pressure, and inhibits platelet aggregation. It is used to study the physiological and pathophysiological roles of NO in cardiovascular function, neurotransmission, and inflammation. Its short half-life makes it suitable for acute NO delivery studies. |
| Enzyme Assay |
In vitro enzyme assays with MAHMA NONOate typically involve measuring the release of nitric oxide and its effects on soluble guanylate cyclase activity. The compound is incubated in buffer at physiological pH, and NO release is measured using chemiluminescence, Griess assay, or electrochemical detection. sGC activity is measured by the conversion of GTP to cGMP, which is quantified by ELISA or radiometric methods.
|
| Cell Assay |
In vitro cell culture experiments with MAHMA NONOate involve treating various cell types including endothelial cells, smooth muscle cells, and neuronal cells with the compound. Cells are treated with various concentrations for defined periods, and endpoints include assessment of cGMP levels, vasodilation (in smooth muscle cells), cell viability, and gene expression changes. These experiments characterize the cellular effects of NO.
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rats anaesthetised with pentobarbitone[2]
Doses: 0.3-10 nmol/kg/min Route of Administration: intravenous (iv) injection; 0.3-10 nmol/kg/min once Experimental Results: Dose-dependently diminished in mean systemic artery pressure and demonstrated a more potent effect than GSNO. Caused dose-dependent inhibition of the response to 0.3 μM/kg ADP. In vivo animal experiments with MAHMA NONOate typically involve administering the compound via intravenous injection or topical application to study its effects on blood pressure, vascular function, and platelet aggregation. Animal models of hypertension, ischemia-reperfusion injury, and inflammation are used to study the therapeutic potential of NO donors. These studies provide insights into the role of NO in various disease states. |
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of MAHMA NONOate are characterized by its rapid release of nitric oxide. It has a half-life of approximately 1-2 minutes at physiological pH and temperature, making it a short-acting NO donor. It is rapidly cleared from the circulation as NO is released and metabolized to nitrate and nitrite. Its short duration of action makes it suitable for acute pharmacological studies.
|
| Toxicity/Toxicokinetics |
MAHMA NONOate has a moderate toxicity profile due to its ability to release nitric oxide, which at high concentrations can be toxic. It is handled as a hazardous chemical and appropriate safety precautions should be taken. It may cause skin and eye irritation. Standard laboratory safety practices, including the use of gloves and eye protection, should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
MAHMA NONOate is a nitric oxide (NO) donor compound used as a pharmacological tool to study the role of NO in various biological processes including vasodilation, neurotransmission, and inflammation. It releases NO in a pH- and temperature-dependent manner with a short half-life. The compound is not a drug and has no approved therapeutic indications. It is available for laboratory research use only.
|
| Molecular Formula |
C8H20N4O2
|
|---|---|
| Molecular Weight |
204.27
|
| Exact Mass |
204.158
|
| CAS # |
146724-86-9
|
| PubChem CID |
135487863
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
301.7±44.0 °C at 760 mmHg
|
| Melting Point |
102-108ºC
|
| Flash Point |
136.3±28.4 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.503
|
| LogP |
0.44
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
14
|
| Complexity |
163
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CNCCCCCCN(C)/[N+](=N/O)/[O-]
|
| InChi Key |
KQHAZGURWZYZJG-BENRWUELSA-N
|
| InChi Code |
InChI=1S/C8H20N4O2/c1-9-7-5-3-4-6-8-11(2)12(14)10-13/h9,13H,3-8H2,1-2H3/b12-10-
|
| Chemical Name |
(Z)-hydroxyimino-[methyl-[6-(methylamino)hexyl]amino]-oxidoazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8955 mL | 24.4774 mL | 48.9548 mL | |
| 5 mM | 0.9791 mL | 4.8955 mL | 9.7910 mL | |
| 10 mM | 0.4895 mL | 2.4477 mL | 4.8955 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
